Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 17, Issue 4, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-015-0500-2
Keywords
FXR; Obetacholic acid; Bile acid; NAFLD; NASH; Alcoholic hepatitis
Categories
Funding
- National Institutes of Health (NIH) [K08-AA021424, P30-DK-50306]
- Robert Wood Johnson Foundation [71586]
Ask authors/readers for more resources
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and a risk factor for both cardiovascular and hepatic related morbidity and mortality. The increasing prevalence of this disease requires novel therapeutic approaches to prevent disease progression. Farnesoid X receptors are bile acid receptors with roles in lipid, glucose, and energy homeostasis. Synthetic farnesoid X receptor (FXR) agonists have been developed to specifically target these receptors for therapeutic use in NAFL D patients. Here, we present a review of bile acid physiology and how agonismof FXR receptors has been examined in preclinical and clinical NAFLD. Early evidence suggests a potential role for synthetic FXR agonists in the management of NAFLD; however, additional studies are needed to clarify their effects on lipid and glucose parameters in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available